LDL-Apheresis: Technical and Clinical Aspects by Bambauer, Rolf et al.
The Scientiﬁc World Journal
Volume 2012, Article ID 314283, 19 pages
doi:10.1100/2012/314283 The  cientiﬁcWorldJOURNAL
Review Article
LDL-Apheresis:Technicaland ClinicalAspects
Rolf Bambauer,1 CarolinBambauer,2 Boris Lehmann,3 Reinhard Latza,3 andRalfSchiel4
1Institute for Blood Puriﬁcation, Saar, 66424 Homburg, Germany
2Formerly Main Hospital Darmstadt, 64283 Darmstadt, Germany
3Laboratory of Medicine, 66386 St. Ingbert, Germany
4Inselklinik Heringsdorf GmbH, 17424 Seeheilbad Heringsdorf, Germany
Correspondence should be addressed to Rolf Bambauer, rolf.bambauer@t-online.de
Received 30 October 2011; Accepted 3 January 2012
Academic Editor: Kathleen M. Botham
Copyright © 2012 Rolf Bambauer et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Theprognosisofpatientssuﬀeringfromseverehyperlipidemia,sometimescombinedwithelevatedlipoprotein(a)levels,andcoro-
nary heart disease refractory to diet and lipid-lowering drugs is poor. For such patients, regular treatment with low-density lipo-
protein (LDL) apheresis is the therapeutic option. Today, there are ﬁve diﬀerent LDL-apheresis systems available: cascade ﬁltra-
tion or lipid ﬁltration, immunoadsorption, heparin-induced LDL precipitation, dextran sulfate LDL adsorption, and the LDL
hemoperfusion. There is a strong correlation between hyperlipidemia and atherosclerosis. Besides the elimination of other risk
factors, in severe hyperlipidemia therapeutic strategies should focus on a drastic reduction of serum lipoproteins. Despite maxi-
mum conventional therapy with a combination of diﬀerent kinds of lipid-lowering drugs, sometimes the goal of therapy cannot
be reached. Hence, in such patients, treatment with LDL-apheresis is indicated. Technical and clinical aspects of these ﬁve diﬀerent
LDL-apheresis methods are shown here. There were no signiﬁcant diﬀerences with respect to or concerning all cholesterols, or tri-
glycerides observed. With respect to elevated lipoprotein (a) levels, however, the immunoadsorption method seems to be most
eﬀective. The diﬀerent published data clearly demonstrate that treatment with LDL-apheresis in patients suﬀering from severe
hyperlipidemia refractory to maximum conservative therapy is eﬀective and safe in long-term application.
1.Introduction
In 1985, Brown and Goldstein were awarded the Nobel Prize
for medicine for their excellent work on the regulation of
cholesterol metabolism. On the basis of numerous studies,
they were able to demonstrate that circulating low-density
lipoprotein (LDL) is absorbed into the cell through receptor-
linked endocytosis [42–44]. The absorption of LDL into the
cell is speciﬁc and is mediated by a LDL receptor. In patients
with familial hypercholesterolemia, this receptor is changed,
and the LDL particles can no longer be recognized. Their
absorption can thus no longer be mediated, leading to an ac-
cumulation of LDL in blood.
Furthermore, an excess supply of cholesterol also blocks
the 3-hydrox-3 methylglutaryl-Co enzyme A (HMG CoA),
reductase enzyme, which otherwise inhibits the cholesterol
synthesis rate. Brown and Goldstein also determined the
structure of the LDL receptor [42, 44, 45]. They discovered
structural defects in this receptor in many patients with
familialhypercholesterolemia[43].Thus,familialhyperchol-
esterolemia was the ﬁrst metabolic disease that could be
tracked back to the mutation of a receptor gene. Through
many epidemiological studies, not only was the importance
of cholesterol—and particularly that of LDL—in the devel-
opment of coronary sclerosis qualitatively substantiated, but
also a constant connection between cholesterol levels and
coronary morbidity was established. The LDL concentration
in blood is thought to be responsible for the development
of arteriosclerosis and coronary heart disease, in particular
[46–49].
Familialhypercholesterolemia(FH)isanautosomaldom-
inant disorder associated with well-characterized mutations
of hepatocyte apolipoprotein-B (apo-B) receptors resulting
in decreased LDL removal by the liver. FH exhibits a gene
dosage eﬀect. Homozygotes may have cholesterol in the
range of 650–1,000mg/dL, xanthoma by the age of 4 years,
and death from coronary heart disease by the age of 20.
Heterozygotes may have cholesterol in the range of2 The Scientiﬁc World Journal
Table 1: Extracorporeal methods for elimination of LDL cholesterol [1].
Year Authors Method Advantage Disadvantage
1967 De Gennes et al. [2] Plasmapheresis Quick and well-tolerated elimination
of pathologic substances
Unselectivity, danger of infection,
bleeding, and risks of human albumin 1975 Thompson et al. [3] Plasmapheresis
1980 Agishi et al. [4] Cascade ﬁltration Semiselectivity Danger of infection and low
eﬀectiveness
1981 Stoﬀel and Demant [5] Immunoadsorption Selectivity, eﬀectiveness, regeneration,
and reusability Expensive technology
1983 Borberg et al. [6] Immunoadsorption
1983 Wieland and Seidel [7] Heparin-induced LDL
precipitation (HELP) Selectivity and eﬀectiveness Expensive technology
1985 Nose et al. [8] Thermoﬁltration Selectivity and eﬀectiveness
Outdated technology, behavior of
macromolecules under heat unknown
and not available
1985 Antwiller et al. [9] Dextransulfate-induced
LDL precipitation Selectivity and eﬀectiveness Expensive technology and not
available
1987 Mabuchi et al. [10]
Dextransulfate LDL
adsorption
(liposorber-LA 15)
Selectivity and eﬀectiveness Expensive technology
1993 Bosch et al. [11] LDL hemoperfusion
(DALI)
Selectivity, eﬀectiveness, and simple
technology Unknown
2003 Otto et al. [12] LDL hemoperfusion
(liposorber D)
Selectivity, eﬀectiveness, and simple
technology Unknown
Table 2: Possible indications for extracorporeal elimination of
Cholesterols [1].
Dyslipoproteinemia
Primary Secondary
Familial hypercholesterolemia Endocrinological diseases
Familial apo-100 defect Diabetes mellitus
Polygenetic hypercholesterolemia Nephrotic syndrome
Familial combined
hypercholesterolemia
Renal-, heart
transplantation
Isolated lipoprotein (a) elevation Hemodialysis
250–550mg/dL,xanthomabytheageof20years,andathero-
sclerosis by the age of 30 [40]. Through numerous epidemi-
ological examinations, the importance of cholesterol—and
ofLDLinparticular—inthedevelopmentofcoronarysclero-
sis has not only been qualitatively substantiated, but also a
continuing relationship between cholesterol levels and coro-
nary morbidity has been established [50]. The LDL concen-
tration in the blood is particularly signiﬁcant in the develop-
ment of arteriosclerosis and especially of coronary heart
disease.
The insight into these pathophysiological processes
spurredaninnovativeimpetusthroughoutboththepharma-
ceutical and medical industries. This innovation was aimed
on one hand at metabolizing LDL intravascularly through
medication or at inhibiting cholesterol synthesis and on the
other hand at eliminating cholesterol from the intravascular
spaces. There are various methods for the extracorporeal
elimination of cholesterol, which are listed in Table 1.T h e
standard therapy of patients with homozygous and severe
heterozygous FH has been diet, lipid-lowering drugs, and
LDL-apheresis. The authors will present here the diﬀerent
artiﬁcial extracorporeal methods for LDL-cholesterol elim-
ination, which had inﬂuenced the prognosis of the primary
and secondary dyslipoproteinemia tremendously (Table 2).
All the techniques described here are eﬀective and well
tolerated. Based on an average drop in cholesterol of 50–
60 percent per session, a treatment interval of 7–14 days is
advisable. The constant reduction of cholesterol is meant,
above all, to prevent the progression or the development of
atherosclerosis. By lowering the cholesterol from 400mg/dL
to200mg/dL,treatmentcanalmostdoubleapatient’slifeex-
pectancy, according to at least one study [51]. A large dis-
advantage is the high costs of the diﬀerent artiﬁcial methods,
therefore the most LDL-apheresis treatments are performed
in the industrialized nations.
2. Epidemiology and Pathophysiology
FH is one of the most common inherited disorders; there are
10,000,000 people with FH worldwide, mainly heterozygous.
The most common FH cause is mutations along the entire
gene that encode for LDL receptor protein, but it has been
also described that mutations in apolipoprotein B and pro-
tein convertase subtilisin/hexin type 9 genes produce this
phenotype [52]. An increased level of cholesterol is almost
always due to an increase in circulating LDL, usually with
simultaneous increase in VLDL and decrease in HDL. This
constellation accelerates the development of arteriosclerosis
and, in particular, coronary heart disease. Heterozygous fa-
milial hypercholesterolemia occurs with a frequency of
1:500 and the homozygous form with a frequency of
1:1,000,000. Patients with homozygous, familial hyperchol-
esterolemia nearly all die before the age of 30.The Scientiﬁc World Journal 3
Despite substantial progress in diagnosis, drug therapy
and cardiosurgical procedures, atherosclerosis with myocar-
dial infarction, stroke, and peripheral vascular disease still
maintain its position at the top of morbidity and mortality
statistics in industrialized nations [53]. Established risk fac-
tors widely accepted are smoking, arterial hypertension, dia-
betes mellitus, and central obesity. There is a strong correla-
tion between hyperlipidemia and atherosclerosis. The role of
cholesterol-bearing lipoproteins in atherogenesis is well esta-
blished, and in past years the mode of interaction of these
particles with cells has been elucidated. It is suggested that
elevated lipid concentrations in the serum lead to their
accumulation in the intima of arteries that results in the
development of atherogenic plaques. These alterations seem
to be accompanied by changes in vessel tone and endothelial
regulation [54–57].
Ithasbeenadequatelydemonstratedthatdyslipoprotein-
emia plays a key role in the pathogenesis of atherosclerosis
and coronary heart disease. Previously, emphasis was placed
on increase in the LDL particles. High LDL, low high-density
lipoprotein (HDL), and hypertriglyceridemia aﬀect each
other. There is a strong correlation between hyperlipidemia
and atherosclerosis [53, 54, 58, 59]. Various researchers have
investigated the eﬀects of hyperlipidemia on endothelial
function and the relevance of these eﬀects on early events
in atherogenesis [51, 59–64]. Vascular endothelium is con-
sidered to be the largest endocrine, paracrine, and autocrine
participant in the regulation of numerous homeostatic vas-
cular functions [65]. Endothelial cells sense changes in
hemodynamic forces such as pressure and shear stress as well
as circulating and locally formed vasoactive substances re-
leasedbybloodcells.Inresponsetothesestimuli,endothelial
cells synthesize and release biologically active substances
suchasnitrideoxide(NO),prostacyclin,endothelium-deriv-
ed hyperpolarizing factor, endothelins, prostaglandin H2,
thromboxane A2, heparin sulfate, transforming growth
factor, vascular endothelial growth factor, basic ﬁbroblast
growth factor, platelet-derived growth factor, tissue plasmin-
ogen activator, plasminogen activator inhibitor-1, oxygen-
free radicals, and others [66]. These substances modulate
vascular tone through their relaxing and contracting actions
as well as vascular structure through production of growth-
promoting and growth-inhibiting factors. In hypercholes-
terolemic patients, intravenous reconstituted HDL infusion
rapidly normalizes endothelium-dependent vasodilation by
increasing NO bioavailability. This may in part explain the
protective eﬀect of HDL on coronary heart disease and illus-
trates the potential therapeutic beneﬁt of increasing HDL
in patients at risk from atherosclerosis [67]. The endothe-
lium also regulates hemostasis and thrombosis through its
antiplatelet, anticoagulant, and ﬁbrinolytic functions as well
as inﬂammation through the expression of chemotactic and
adhesion molecules [68, 69].
Endothelium plays a key role in vascular homeostasis.
The endothelium is in a strategic location between the blood
and vascular smooth muscle; thus it is a primary target for
injury from mechanical forces and processes related to car-
diovascularriskfactors[65].Itissuggestedthatelevatedlipid
concentration in the serum lead to their accumulation in the
intima of arteries, resulting in the development of athero-
genic plaques. These alterations seem to be accompanied by
changes in vessel tone and endothelium regulation [53, 56,
70]. Elevated levels of LDL increase the risk of the develop-
ment and progression of coronary heart disease (CHD) [58,
65]. More recent studies have demonstrated the termination
of progression, and even regression, of coronary atheroscle-
rosis as a consequence of lipid lowering [71–73].
Apositivecorrelationbetweenelevatedtriglycerideblood
levels and heart attacks has been established in numerous
studies [51, 74]. Hypertriglyceridemia is prevalent in 18.6
percentofmenand4.2percentofwomenbetweentheagesof
16 and 65. Of particular importance is that increased trigly-
ceridesareoftenaccompaniedbylow-HDLcholesterolblood
levels. Elevated triglycerides (TG) represent a useful marker
for risk of CHD, particularly when HDL levels are low [75].
The strong association between the ratio of TG/HDL and the
risk of CHD suggests a metabolic interaction between the
TG—and cholesterol ester-rich lipoproteins in increasing
risk of CHD [76]. Dyslipoproteinemia in combination with
diabetes mellitus causes a cumulative insult to the vascula-
ture resulting in more severe disease which occurs at an
earlier age in large and small vessels as well as capillaries. The
most common clinical conditions resulting from this com-
bination are myocardial infarction and lower extremity vas-
cular disease. Ceriello et al. show an independent and cumu-
lative eﬀect of postprandial hypertriglyceridemia and hyper-
glycemia on endothelial function, suggesting oxidative stress
as common mediator of such eﬀect [77]. The combination
produces greater morbidity and mortality than either alone.
Early diagnosis of each condition and aggressive medical
management is required to achieve an improved prognosis
[78].
As an antiatherogenic factor, HDL cholesterol correlates
inversely to the extent of postprandial lipemia. A high con-
centration of HDL is a sign that triglyceride-rich particles are
quickly decomposed in the postprandial phase of lipemia.
Conversely, with a low HDL concentration this decomposi-
tion is delayed. Thus, excessively high triglyceride concentra-
tions are accompanied by very low HDL counts. This com-
bination has also been associated with an increased risk of
pancreatitis [55].
T h ei m p o r t a n c eo flipoprotein (a) (Lp(a)) as an athero-
genic substance has also been recognized in recent years.
Lp(a) is very similar to LDL. But it also contains Apo(a),
which is very similar to plasminogen, enabling Lp(a) to bind
to ﬁbrin clots. Binding of plasminogen is prevented and
ﬁbrinolysisobstructed.Thrombiareintegrated into thewalls
of the arteries and become plaque components. Thus, many
studies show that high Lp(a) concentrations are associated
with an early occurrence of coronary heart disease and apo-
plectic insult [79]. Due to the structural similarity between
Apo(a) and a protein of the ﬁbrinolytic system, it has not
yetbeenpossibletodeﬁnitelyclarifywhetherLp(a)isathero-
genic, thrombogenic, or both.
Uttermann found six diﬀerent Lp(a) phenotypes: S4, S3,
S2, S1, B, and F. They investigated the inﬂuences of these
phenotypes on the Lp(a) levels and found that phenotypes
S1, S2, and B were associated with high, and phenotypes S44 The Scientiﬁc World Journal
and S3 with low Lp(a) concentrations [80]. It has not yet
been determined whether CHD is mainly primarily associat-
ed with Lp(a) levels or with the phenotypes. It can be con-
cluded that high levels of Lp(a) are associated with CHD; the
isoforms S2, S1, B, F are linked to CHD; and patients with
prematureCHDshowedthehighestLp(a)levelsaswellasthe
isoforms S2, S1, B, and F [81, 82]. Several mechanisms have
been postulated: blocking of plasminogen, a binding site on
ﬁbrin clots, interaction with other coagulation proteins, and
hepatic growth factor [83, 84]. Grainger et al. showed that
Lp(a) and Apo A enhance proliferation of human smooth
muscle cells in culture by inhibiting the activation of plas-
minogen to plasmin, thus blocking the proteolytic activation
of transforming growth factor-β (TGF-β), an autocrine inhi-
bitor of human vascular smooth muscle cells. The activa-
tion of TGF-β is inhibited in the aortic wall and serum of
mice expressing Apo A as a consequence of Apo (a) inhibi-
tion [85, 86].
In the last years, diﬀerent studies have shown that Lp(a)
is a major independent risk factor for atherosclerosis, in-
creasing cardiovascular and atherovascular morbidity and
mortality at a younger age [80, 81, 87, 88]. In two large con-
trol studies in Finland and USA, Lp(a) was not associated
with an increased cardiovascular risk [54, 89]. Both popula-
tions consisted of patients over 40 years of age without signs
of cardiovascular disease at entry. The results of these stud-
ies indicate that high Lp(a) levels that have not led to sym-
ptomatic arteriosclerosis before the age of 40 years (and
thus also led to exclusion from this study), might no longer
play a role as a risk factor. After Tsimikas et al., the associa-
tion of the oxidized phospholipid: apo B-100 ratio with ob-
structive coronary artery disease was independent of all cli-
nical and lipid measures except one, Lp(a). However, among
patients of 60 years of age or younger, the oxidized phos-
pholipid: apo B-100 ratio remained an independent predic-
tor of coronary artery disease [90].
OtherinvestigatorshaveshownthatLp(a)playsanimpor-
tant role in the progression of atherosclerosis. Gaubatz et al.
observed that the metabolic fate of the Lp(a)-triglyceride-
rich lipoprotein complex, which is more abundant in hyper-
triglyceridemia, may be diﬀerent from that of conventional
Lp(a) and may contribute uniquely to the progression or
severity of cardiovascular disease [91]. Komai et al. demon-
strated that oxidized Lp(a) is more potent than native Lp(a)
in stimulating vascular smooth cells. Oxidized Lp(a) may
play an important role in the pathogenesis of vascular dis-
ease [92]. Elevated Lp(a) levels are correlated with the extent
of CHD and the mortality of these patients [93–95]. Ducas
et al. reported of an acquired Lp(a) excess in patients with
renaldiseaseasamarkerforcardiovascularrisk[95].Theele-
vation of plasma Lp(a) concentrations in patients with renal
diseases appears to be related to proteinuria and is, therefore,
amenable to treatment. High Lp(a) levels in renal disease
suggest an important role of the kidneys in the metabolism
[96,97].AmongolderadultsintheUnitedStates,anelevated
level of Lp(a) lipoprotein is an independent predictor of
stroke,deathfromvasculardisease,anddeathfromanycause
in men, but not in women. These data support the use of
Lp(a) lipoprotein levels in predicting the risk of these events
in older men [98].
Thus far, no suﬃciently drug therapy has been available
to decrease high Lp(a) levels. N-acetylcysteine has been
shown to induce a dose-dependent reduction in Lp(a) levels
about seven percent by causing dissociation of the Apo A by
cleavage of disulﬁde bonds [99]. This report has been con-
tradicted by that of Wiklund et al. [84]. Very high Lp(a)
levels can only be normalized by plasma exchange or LDL-
apheresis [100].
Another strong risk factor for accelerated atherogenesis,
which must be mentioned here, are the widespread high
homocysteine levels found in dialysis patients [101]. This risk
factor is independent of classic risk factors such as high chol-
esterol and LDL levels, smoking, hypertension, and obesity,
and much more predictive of coronary events in dialysis pa-
tients than are these better-known factors. Homocysteine is a
sulfur aminoacid produced in the metabolism of methionine
[102]. Under normal conditions, about 50 percent of homo-
cysteineisremethylatedtomethionineandtheremainingvia
the transsulfuration pathway [103]. Vitamins are important
cofactors for the enzymes in the methionine metabolism
(folic acid and vitamin B12 for the remethylation pathway
and vitamin B6, or pyridoxine, for the transsulfuration path-
way). The kidney is an important metabolic site for removal
(up to 70 percent) of plasma homocysteine [104]. In many
patients, the therapy with vitamins B6 and B12 and folic acid
is suﬃcient.
Deﬁning hyperhomocysteinemia as levels greater than
the 90th percentile of controls and elevated Lp(a) level as
greater than 30mg/dL, the frequency of the combination in-
creased with declining renal function. Fifty-eight percent of
patients with a GFR less than 10mL/min had both hyper-
homocysteinemia and elevated Lp(a) levels, and even in pa-
tientswithmildrenalimpairment,20percentofpatientshad
both risk factors present [105].
The discovery of these pathophysiological processes has
led to a surge in innovation in pharmaceutics and medical
technology aimed, not only at metabolization of LDL intra-
vascularthroughmedicationorinhibitionofcholesterolsyn-
thesis, but also at the elimination of cholesterol from the
intravascular area with extracorporeal bioartiﬁcial methods.
3. LDL-Apheresis Therapy
Coronary heart disease remains one of the main causes of
death in the mortality statistics of the industrial nations, des-
pite considerable progress in diagnostics, development of
new medications, such as HMG-CoA-reductase inhibitors as
well as cardiosurgical measures. Cholesterol concentrations
of over 200mg/dL represent an increased coronary risk. This
risk is double at cholesterol values between 200–250mg/dL
and fourfold at values of 250–300mg/dL [106]. In addition
to familial disposition, other risk factors that contribute to
coronary heart disease are smoking, adiposity, diabetes mel-
litus, stress, reduced HDL, increased Lp(a), and ﬁbrinogen.
Usually the severe forms of hypercholesterolemia are
due to a relative or absolute reduction of LDL receptors inThe Scientiﬁc World Journal 5
the liver resulting in a decreased plasma clearance of lipids
[43, 44, 107]. For these patients, reduction of intake dietary
fats is advised. Depending on type of condition, various
medications are available, such as colestyramin, colestipol,
β-ﬁbrates,fenoﬁbrate,nicotinicacid,β-pyridylcarbinol,pro-
bucol, and D-thyroxine. Since the introduction of HMG-
CoA-reductase inhibitors, which can also be combined with
other lipid-lowering drugs, LDL reduction up to 50 percent
of the original concentration can be achieved. In many cases,
this appears to be suﬃcient. Numerous studies based on
largenumbersofpatientshaveinvestigatedtheeﬀectivityand
safety of the various HMG-CoA-reductase inhibitors. In
these studies, investigators tested Fluvastatin, Lovastatin,
Pravastatin, and Simvastatin [108–111]. During the testing
period, numerous side eﬀects like diarrhea, obstipation,
other gastrointestinal diseases, myositis, rhabdomyolysis,
and others were observed [112]. As a result of the clariﬁ-
cation of the connection between hypercholesterolemia and
coronary heart disease, numerous studies have been carried
outinrecentyearswithvariousmedications[113–117].With
theintroductionofselectiveandsemiselectiveextracorporeal
elimination methods for cholesterol, LDL, Lp(a), and tri-
glycerides, all forms of previous therapy-resistant hyper-
cholesterolemia can now be eﬀectively treated [118].
Severe heterozygous forms of familial hypercholestero-
lemia or other forms of dyslipoproteinemia with cholesterol
values between 250 and 600mg/dL are also to be allocated to
thetherapygroupforLDL-apheresis.Principally,theseforms
ﬁrst require maximum dietetic and medicational therapy, for
example with, 24–32g ion exchanger in combination with
40–80mg CSE inhibitors. If, despite this maximum therapy
or due to therapy intolerance, LDL cannot be constantly held
below 200mg/dL, then LDL-apheresis is indicated. Only in
cases of exceptional circumstances should patients over 60
years of age be given LDL-apheresis treatment; however, di-
agnosis should be supported by corresponding examina-
tions, and the patient should be a nonsmoker. All patients
should be placed under cardiological observation with ECG
underexercise,thalliumscintigraphy,and,possibly,coronary
angiography, to register reduced progression or the desired
regression of the coronary heart condition. There have been
thus far not enough long-term results from controlled inter-
ventional studies with regard to the expected positive inﬂu-
ence of LDL-apheresis implementation in coronary mor-
bidity and mortality.
The various LDL-apheresis systems have only been part
of clinical routine for the past 25 years. The advantages can,
however, be estimated from the Framingham study [114,
119]. The quotient relevant for cost-eﬀective assessment:
[cost of treatment—costs saved]: [improvement in life qual-
ity] cannot be exactly calculated at present. To calculate it,
detailed information is required about the expenses saved
through illnesses avoided (heart attack, angina pectoris, and
premature coronary death). The standard therapy for FH be-
sides diet is, lipid-lowering drugs the LDL-apheresis. Up to
now only cascade ﬁltration immunoadsorption, heparin-in-
duced LDL precipitation, LDL adsorption through dextran
sulfate, the DALI hemoperfusion system, and the Liposorber
D system have been of clinical relevance. The position of
theestablishedLDL-apheresissystemswasimprovedbytech-
nical processes or documentation of beneﬁcial clinical ef-
fects. For this reason, we only discuss the clinically relevant
techniques here. The requirement that the original level of
cholesterol is to be reduced by at least 60 percent is fulﬁlled
by all the systems listed in Table 3.
4. CascadeFiltration
Cascade ﬁltration, membrane diﬀerential ﬁltration (MDF)
or double ﬁltration plasmapheresis seems to be superior to
conventional plasmapheresis but less eﬀective than adsorp-
tion or precipitation techniques [118–120]. The cascade ﬁl-
tration was developed by Agishi et al. in Japan and was the
ﬁrst semiselective technique used for treating hypercholes-
terolemia [4]. The secondary membrane in cascade ﬁltration
has a cutoﬀ of approximately one million daltons. LDL chol-
esterol has a molecular weight of approximately 2,300,000
daltons and is thus retained by this membrane. All other
molecules, which are larger than one million daltons are also
retained, while plasma components smaller than one million
daltons pass through the membrane and are returned to the
patient. Thus, with plasma separation of 2,500–3,000mL,
total cholesterol can be reduced by approximately 35–50 per-
cent of the original value and LDL cholesterol by approxi-
mately 30–45 percent thereof (Table 3)[ 121]. Due to irreg-
ular pore distribution with diﬀerent diameters in the sec-
ondary membrane, plasma components with smaller molec-
ular weight can also be retained, such as ﬁbrinogen (MW:
˚ A 340,000), HDL (MW: ˚ A 400,000), and IgM (MW: ˚ A
1,000,000). In the treatment with 3,000mL of plasma not
only large amounts of albumin but also other substances, as
shown in Table 3 are reduced [122–125]. Given the cardio-
vascular risk factor, it appears beneﬁcial to reduce ﬁbrino-
gen, while decreasing HDL, a protective factor against ath-
erosclerosis, appears to be harmful [123]. It is necessary to
develop more eﬀective secondary membranes with exactly
deﬁned pores to improve the selectivity of cascade ﬁltration.
G e i s se ta l .f o u n dt h a tM D Fi sa ne ﬀective method to lower
elevated concentrations of atherogenic lipoproteins. The
concomitant loss of other macromolecules transiently im-
proves hemorrheology but demands a close monitoring of
immunoglobulin concentrations as a safety parameter [126].
Withthenewsyntheticsecondarymembranessuchasthe
lipidﬁlter EC-50 (Asahi, Japan), and new types of machines,
better eﬀectiveness and selectivity in the separation of the
blood components can be reached in the treatment of hyper-
cholesterolemia. This cascade ﬁltration system is called lipid
ﬁltration [127]. Klingel et al. observed during an extension
period of 5 weeks with lipid ﬁltration using the lipid ﬁlter
EC-50 and treating a higher mean plasma volume of
3,370mL, lipid ﬁltration led to an increased reduction rate
particularly for LDL cholesterol. Fibrinogen and Lp(a), with
pretreatment levels of HDL cholesterol, total protein, and
immunoglobulinsremainedunchangedandwerenotsigniﬁ-
cantly diﬀerent from the values before the last apheresis
[128]. MDF or lipid ﬁltration is as safe and eﬀective as the
HELP-system with respect to the extracorporeal removal6 The Scientiﬁc World Journal
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of LDL-cholesterol, Lp(a), ﬁbrinogen, by treating identical
plasma volumes [127]. Hibino et al.observed that LDL-chol-
esterol removal by double ﬁltration plasmapheresis might
suppress inﬂammation and improve tissue environment in
visceral adipose and liver tissue with fatty deposits [129].
A new term rheopheresis was created for special method
of cascade ﬁltration designed to reduce blood viscosity in the
managementofdiseaseswithimpairedmicrocirculation,like
age-related macular degeneration, diabetes mellitus, coro-
naryarterydisease,peripheralarterialocclusivedisease,cere-
bro-vascular stroke, and sudden deafness. Especially in the
treatmentofdiabeticretinopathyandoftheage-relatedmac-
ular degeneration, the results with the rheopheresis are very
promising [130, 131]. Terai et al. observed that changes in
retinal vascular diameter seem to be associated with the sys-
temic eﬀect of a single LDL-apheresis. Vasodilatation of the
arterioles and the venules improved after LDL-apheresis, in-
dicatinganimprovementofocularperfusioninpatientswith
hypercholesterolemia [132].
Thedevelopmentofnewmembraneswithvariouscutoﬀs
and improved technical apparatus will probably allow for
safeandeﬀectivedoubleortripleﬁltrationinthenearfuture.
The implementation of specially constructed hollow ﬁbres
made of glass will also facilitate a more eﬀective cascade ﬁl-
tration. These hollow glass ﬁbres will be manufactured with
pores of exactly deﬁned measurements, which will enable
exact ﬁltration. Thus, it will be possible to manufacture vari-
ous hollow ﬁbre modules with varying pore sizes, and which
are reusable. On one hand, selective plasma separation will,
drastically reduce the danger of hepatitis and sensibilization
by foreign proteins. The biggest advantage clinically is that
physiological proteins such as clotting factors, hormones,
and enzymes, and other such elements will have to a lesser
extent.
5. Immunoadsorption
This method was ﬁrst described in 1981 by Stoﬀel and De-
mant and by Borberg et al. in 1983 as LDL-apheresis with
anti-LDL sepharose columns [5, 6]. Immunoadsorption
means that, after primary separation, the plasma is perfused
through sepharosis columns coated with LDL antibodies.
TheLDLmoleculesintheplasmaareadsorbedontotheanti-
bodies on the columns. This is a reversible antigen-antibody
bond accord based on the principle of aﬃnity chromatog-
raphy. Antibodies against the protein component in human
LDL cholesterol (apolipoprotein B 100) gained from sheep
arecovalentlyboundtosepharoseparticles.Thesearehetero-
clonal sheep antibodies against apoprotein B, which are
bound to sepharose after cyanogen bromide activation. In
onecolumn,threegramsofLDLcholesterolcanbeadsorbed.
Both columns contain 300–320mL of sepharose particles.
Before the column is saturated with the absorbed lipo-
proteins (600–800mL plasma), the plasma ﬂow is switched
to the other column; while one column is used for adsorp-
tion,theoﬀ-linec ol umnisgenerat edwithne utralsalinebuf-
fersolution,glycinebuﬀer(pH2.4),andneutralbuﬀeragain.
The treated plasma is then mixed with the cellular compo-
nents of the blood and returned to the patient. The entire
procedure takes 2.5–3 hours via a computerized apheresis
monitor. After the treatment, the columns are rinsed, and
after the same procedure, ﬁlled with sterile solution. The im-
munoadsorption columns can be used for a minimum of 40
treatments.
The antigen-antibody bound is reversed by using a mix-
ture of glycine and hydrochloric acid with a pH of 2.8. The
pH is then increased to 7.4 using a sodium chloride solution,
buﬀered with phosphate, and rinsed with physiological com-
mon salt solution. This procedure restores the binding capa-
city of the columns and prepares them for use again. In this
way, any required volume of plasma can be perfused in one
treatment session (3–10L). Upon conclusion of the treat-
ment, the columns are regenerated, sterilized, and can be im-
plemented again. The advantage of this method is the selec-
tivity,eﬀectiveness,andregeneratingcapacityofthecolumns
(Table 1). The disadvantage is the high expenditure required
not only for the treatment itself, but also for the regeneration
process. The immunoadsorption columns are approved for
regular and continued use [133].
Given the high cost of the columns, implementation of
this system is only viable on a long-term basis, that is to say,
at least 40 times per patient. At a perfusion volume of 3–
6 liters per session, the LDL cholesterol is reduced to 30–
40 percent of the original level. HDL, serum proteins, im-
munoglobulins, and ﬁbrinogen, and so forth drop by ap-
proximately 15–20 percent and return to their normal level,
however,afterapproximately24hours.Paruseletal.reported
ﬁndings of a temporary activation of the complement system
and a drop in leucocytes [134]. Resulting side eﬀects or other
complications have, only been seldom reported, however
[13].
Two diﬀerent systems are currently available, the LDL-
Therasorb system (Miltenyi Biotec, Germany) and the LDL-
and Lp(a)-Excorim system (Fresenius, Germany). The
matrix sepharose is coupled with speciﬁc antihuman apo-
lipoprotein B-100 or antihuman Lp(a) sheep antibodies.
Both systems are safe and eﬀective in clinical use, even in
long-term treatment. Indications for the extracorporeal eli-
mination of LDL cholesterol are primary and secondary dys-
lipoproteinemia, and for the Lp(a) IA the solitary familial
Lp(a) elevation. Table 4 shows a compilation of some of the
results of IA. Jovin et al. found no signiﬁcant variation of
selectivity. The eﬃcacy of the LDL-apheresis immunoad-
sorption columns did not decrease after 60 treatments ses-
sions. The columns selectivity also remained unchanged
[135]. The advantages of immunoadsorption are high select-
ivity and eﬀectiveness for adsorption of all apo-B-containing
lipoproteins. This treatment showed a beneﬁcial eﬀect of
long-term LDL-apheresis on atherosclerotic vascular disease
[15, 136, 137].
6. Lipoprotein (a)-Apheresis
Lipoprotein (a) (Lp(a)) represents a class of lipoprotein par-
ticles which have lipid composition similar to LDL and8 The Scientiﬁc World Journal
Table 4: Immunoadsorption (Therasorb, Miltenyi, Germany) in
hypercholesterolemia (selection of literature).
Year Authors Patients
(n)
Duration
of therapy
(years)
Reduction
of LDL
(%)
1988 Borberg et al. [13] 5 3–5 52–67
1988 Oette and Borberg [14]1 0 5 – 8 7 1
1990 Richter et al. [15]8 1 – 3 5 6
1993 Bambauer et al. [16] 4 1-2 55–58
1996 Richter et al. [17] 18 8.6 60–70
a protein moiety, apo-B 100, covalently linked to apo(a),
a glycoprotein with striking structural similarities to plas-
minogen [138]. High plasma levels of Lp(a) are associated
with an increased risk for atherosclerotic coronary heart
disease (CHD) by a mechanism yet to be determined [139].
Because of its structural properties, Lp(a) can have both
atherogenic and thrombogenic potentials [81]. The means
for correcting the high plasma levels of Lp(a) are still limited
in eﬀectiveness. All drug therapies tried thus far have failed.
The most eﬀective therapeutic methods in lowering Lp(a)
aretheLDL-apheresismethods.Since1993,specialimmuno-
adsorption polyclonal antibody columns (Pocard, Moscow,
Russia) containing sepharose bound anti-Lp(a) have been
available for the treatment of patients with elevated Lp(a)
serum concentrations [100, 140].
Monospeciﬁc polyclonal antibody to human Lp(a) was
obtained from immune sheep serum. Pokrovsky et al. des-
cribed preparing immunosorbent by immobilizing of anti-
bodies to Sepharose CL-4B [140]. For the treatment, two
columns are necessary. Each column is ﬁlled with 400mL of
sorbent tested for sterility and pyrogenicity. Anti-Lp(a) im-
munoadsorption columns are reusable. Between the treat-
ments, the columns are stored at 4◦C in storage solution,
which is rinsed prior to each Lp(a)-apheresis procedure. Two
personal columns are assigned to each patient [141].
The numerous studies provide the epidemiological evi-
dence that Lp(a) is an independent risk factor in the patho-
genesis of coronary heart disease and arteriosclerosis. The
individual plasma level is genetically determined. Diet or
available drugs do not inﬂuence the plasma level of Lp(a).
Until today there is only one device available on the market
which allows the speciﬁc removal of Lp(a) from plasma
(Lipopak, Pocard, Moscow, Russia). As with LDL-apheresis
in homozygotes-speciﬁc Lp(a) is a life-saving therapy in
severe cases with elevated Lp(a) as the sole risk factor.
7. Heparin-InducedLDLPrecipitation(HELP)
In 1982, Seidel and Wieland reported on a new method of
extracorporealeliminationoflow-densitylipoproteins[142].
This method was abbreviated HELP. After primary separa-
tion, the plasma is mixed in a ratio of 1:1 with an acetate-
acetic acid buﬀer (pH 4.85), so that the pH of this mixture is
5.1.Then,100,000Uheparinperliterareaddedtothebuﬀer.
Aftertheplasmahasbeenmixedthoroughlywiththeacetate-
aceticacidbuﬀerandheparin,LDLcholesterolprecipitatesin
the acid environment together with ﬁbrinogen and heparin
to form insoluble precipitates. These precipitates are then
removedfromtheplasmabymeansofapolycarbonatemem-
brane. The remaining free heparin is almost completely re-
moved by a heparin absorber (DEAE cellulose). The acidu-
lous plasma is returned to a physiological pH value using bi-
carbonatedialysis,andtheplasma,freeofLDL,isreturnedto
the patient with the blood cells [143]. Although the method
is technically complicated, it is reliable and eﬀective. It is,
however, nonselective for in addition to the cholesterols, C3,
C4, ﬁbrinogen, plasminogen, and factor VIII, and so forth
are also eliminated (Table 3). HDL reaches its original level
after 24 hours, while the ﬁbrinogen concentration only in-
creases gradually; the amount of plasma should, therefore,
be limited to 3 three litres [143].
More recently, a compact unit has been designed that
somewhat reduces the cost of the equipment. The Plasmat
Futura (B. Braun, Germany) is easy to use and safe in handl-
ing. The priming rinsing and reinfusion are fully automated.
The entire treatment uses only disposable material, the
machine does not need descaling or disinfection, and no
piped water supply or reverse osmosis is required. The user is
safely guided through all treatment steps and supported with
message prompts and warnings.
Because C3, C4, ﬁbrinogen, and plasminogen are also
reduced to approximately 50 percent of their original con-
centration as well as cholesterol, LDL and triglycerides, the
technique is not highly speciﬁc [143]. Due to the large drop
in ﬁbrinogen in the HELP process, the amount of plasma per
session is limited to 3 three liters. A treatment using larger
amounts of plasma could lead to bleeding complications.
With this amount of plasma, the cholesterols are reduced as
shown in Table 3. The other factors, like CRP, are also reduc-
ed by approximately 50 percent. In contrast, HDL is only
reducedby10–20percent.Thusfarnoseveresideeﬀectshave
been described; however, occasional shivering and drops in
blood pressure have been observed [22].
Studies on patients undergoing regular extracorporeal
LDL-elimination indicate that the incidence of adverse car-
diovascular clinical events can be reduced much earlier than
by drug therapy alone. These immediate clinical beneﬁts,
which take place directly after the apheresis, cannot be due,
however, to an improvement in coronary morphology (i.e.,
regression of atherosclerotic lesions), since such improve-
mentcanonlybeobservedafterseveralmonthsoftreatments
[22]. The improved myocardial perfusion and clinical symp-
toms after LDL-apheresis is likely due to an improvement in
rheology as well as producing an immediate positive inﬂu-
ence on endothelium function and an increase in the volume
ofvasodilatory,antiaggressivenitrogenmonoxidereleasedor
a reduction in the volume of available endothelin [26, 144].
A more than 60 percent reduction of LDL at weekly intervals
is clearly associated with an early regression of lipid-rich vas-
cular lesions [145]. LDL apheresis reduces the shear-stress of
theﬂowingbloodonvulnerableplaqueseitherbyitseﬀecton
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leading to a lower peripheral arterial resistance. Further-
more, LDL-apheresis eliminates oxidized LDL, which might
counteract plaque stabilization by its inﬂammatory eﬀects.
LDL-apheresis to with coagulation factors normalizes hyper-
coagulatory states, thus preventing atherothrombotic events
at the site of vulnerable or erosive plaques [145].
The safety and long-term applicability of the HELP sys-
tem has been proved in more than 120,000 treatments. Seri-
ous complications have never been observed [20], and the
technology of the equipment has been improved over time.
Many authors have shown that there is clear clinical evidence
that a drastic lowering of LDL concentrations by HELP re-
duces signiﬁcantly the rate of total and coronary mortality as
well as the incidence of cardiovascular events in high-risk
hypercholesterolemic patients [20, 23, 144, 146, 147]. Wang
suggested that simultaneous reduction of proinﬂammatory
and prothrombotic factors with atherogenic lipoproteins by
HELP apheresis may contribute to improvement of endo-
thelial dysfunction and thereby inhibit progression of ath-
erosclerotic lesions and stabilize the existing plague [28].
Otto et al. found that LDL apheresis slightly, but signiﬁcantly
reduced CRP concentrations in patients with CHD on statin
therapy, which may contribute to the stabilization of athero-
sclerosis in hypercholesterolemic patients treated with LDL
apheresis[148].Theseresultsareevenmoreimpressivewhen
known age-related increase in CRP over treatment period is
taken into account [148, 149].
All HELP treatments have demonstrated successful sec-
ondary prevention for patients with familial hypercholes-
terolemia, coronary artery disease, cardiac bypass, or heart
transplantation[23,150,151].Eliminationofﬁbrinogenand
other substances also has an inﬂuence on blood viscosity,
rheology, and erythrocyte aggregation; thus, the microcir-
culatory situation as a whole can be signiﬁcantly improved.
Numerous reports on clinical results with the HELP tech-
n i q u eh a v eb e e np u b l i s h e di nr e c e n ty e a r s[ 18, 146, 152]. A
selection of literature and LDL elimination has been com-
piled in Table 5.S e v e r es i d ee ﬀects are rare: so far, the only
side eﬀects reported have been transient shivering and hypo-
tension. More than 83 percent of the treated patients have
demonstrated clinical improvement.
In 1999, Jaeger et al. published the ﬁrst clinical results
with HELP apheresis in acute cerebral infarction (stroke).
These results are similar to the clinical experience reported
with myocardial ischemia [150]. In the same year, Suckf¨ ull
et al. published a randomized study of the clinical utility of
LDL apheresis in the treatment of sudden hearing loss [153].
Their results suggest that the clinical outcome of the treat-
ment of sudden hearing loss after a single HELP apheresis is
superior to the more expensive treatment with prednisolone,
dextrans, and pentoxifylline. Bianchin et al. found that in
a speciﬁc group of patients with alterations in cholesterol
and/or ﬁbrinogen, the HELP apheresis treatment is a further
option available in sudden sensorineural hearing loss [154].
More studies should be needed to show whether or not the
HELP apheresis will be the most eﬀective treatment for these
diseases.
8.DextranSulfateLow-Density
Lipoprotein (Liposorber)
Mabuchi et al. reported performing a study in 1987 on LDL
absorption with dextran sulphate (Liposorber LA-15,
Kaneka, Japan) [10]. Low-molecular dextran sulfate (MW
4500) can selectively absorb all substances containing apo-
lipoproteinB.Dextransulfateiscovalentlyboundtocellulose
particles. The dextran sulfate was selected as an aﬃnity
ligand of LDL adsorbent for its high aﬃnity and low toxi-
city. The binding mechanism is the direct interaction bet-
ween dextran sulfate and the positively charged surface of
apolipoprotein B-containing lipoproteins (LDL, VLDL, and
Lp(a)). The dextran sulfate has a structure similar to that of
the LDL receptor and seems to act as a type of pseudore-
ceptor [34, 155–157]. Approximately 2.5 grams LDL can be
bound per column. After primary separation, the plasma is
perfundated through the columns, where all material con-
taining Apo-B such as cholesterol, LDL, VLDL, and triglyc-
erides is absorbed. Free of cholesterol, the plasma is returned
to the patient. After 500mL of plasma, the columns are sat-
urated and require regeneration with 4.1 percent NaCl solu-
tion [155]. After rinsing with Ringer’s solution, they are
ready for use again. The eﬀectiveness of this treatment is
good, and cholesterol is eliminated selectively (Table 1). Oc-
casionally, with a perfusion volume of more than four liters,
a marked drop in the Quick level can occur, probably caused
by the absorption of factor VIII [34].
This method has also found widespread clinical use in
recent years [156–161]. Some of the reported LDL reduction
rates have been compiled in Table 6.S i d ee ﬀects are rare and
of a minor nature such as hypotension, nausea, hypogly-
cemia, and light allergic reactions. In a study we conducted
with 20 patients and 955 LDL-apheresis sessions, we observ-
ed that these side eﬀects were observed in 12 percent of all
treatment sessions. A shock situation only arose in 0.4 per-
cent, and in 0.2 percent allergical reactions occurred, which
were easily treated [16]. The dextran-induced allergical re-
actions have not been observed so far. Low-molecular dex-
tran sulfate is much less allergenic than the forms of dextran
which are normally implemented as a plasma expander and
have a higher molecular weight of 40,000 to 80,000. The
advantage of the Liposorber system is the selectivity by eli-
mination of all apo B-containing lipoproteins and the high
eﬀectiveness. A disadvantage is the labor intensive technol-
ogy.
More than 60 percent reduction of the pretreatment
cholesterol values can be achieved by one treatment with the
Liposorber system. The eﬀectiveness of therapy has also been
observed over time in several long-term clinical studies
(Table 6). In more than 75 percent of cases, patients improv-
ed or reached regression of coronary atherosclerosis. The ob-
served side eﬀects were between 0.5 and 4 percent [30, 31,
37, 53, 155]. The Liposorber system is safe and eﬀective, even
inhigh-riskhypercholesterolemiapatients.Althoughevalua-
tion of the eﬀectiveness of LDL-apheresis on coronary arter-
ial lesions has not yet been fully established, evidence is
accumulating to show, not only that it prevents the develop-
ment of coronary heart disease, but also can eﬀect its10 The Scientiﬁc World Journal
Table 5: Clinical results with the HELP-LDL apheresis system (B. Braun, Germany) (literature overview).
Year Authors Diagnosis
HELP
patients
(n)
Drop out
Therapy
duration
(years)
Side eﬀects
(%) Outcome
1987 Eisenhauer et al. [18] FH, CHD 13 — 0.5–1.3 ? 13 improved
1988 Thiery et al. [19] FH, CHD 7 — 0.5–1.0 3.2 7 improved
1991 Seidel et al. [20] FH, CHD 51 5 1.0 2.9 46 improved
1993 Bosch et al. [21] FH, CHD
ESRD 3 (HD) — 1.5 13.0 3 improved
1994 Schuﬀ-Werner et al. [22] FH, CHD 51 12 2.0 2.8 39 improved
1997 Jaeger et al. [23] FH, CHD
HTX 15 — 3.6 — 5 improved
1998 Mellwig et al. [24]F H , C H D 9— ? — 8 i m p r o v e d
1999 Donner et al. [25]F H 4 — ? ? 4 i m p r o v e d
2000 Schettler et al. [26]F H , C H D 1 8—>0.5 — 18 improved
2001 Moriarty et al. [27]F H 4 — 0 . 5 — 4 i m p r o v e d
2008 Wang [28] FH, CHD 22 — 1.0 — 22 improved
ESRD: end-stage renal disease and HTX: heart transplantation.
Table 6: LDL adsorption with dextran sulfate (Liposorber LA-15, Kaneka, Japan) in hypercholesterolemia (selection of literature).
Year Authors Diagnosis Patients
(n) Drop out
Therapy
duration
(years)
Side eﬀects
(%) Outcome
1988 Thompson and
Okabayashi [29] FH, CHD 20 — 2.1 0.5 19 improved
1992 Gordon et al. [30] FH 54 — 0.25 — 54 improved
1994 Daida et al. [31] FH, CHD 66 — 1.0 — 45 improved
1996 Kroon et al. [32] FH, CHD 21 — 2.0 1.3 21 improved
1997 Gordon and Saal [33] FH, CHD 45 4 0.5 4.0 41 improved
Bambauer et al. [34] FH, CHD 120 35 6.0 2.2 85 improved
1998 Mabuchi et al. [35] FH, CHD 130 — 6.0 — 94 improved
1999 Nishimura et al. [36]F H 3 0 5 2 . 3 —4 i m p r o v e d
Richter et al. [37] FH, CHD 8 — 3.0–5.0 — 6 improved
2003 Bambauer et al. [38] FH, CHD 32 — 8.0 0.3 31 improved
2010 Moriarty et al. [39] FH, CHD 10 — 0.5 — 10 improved
regression by lowering of cholesterol to an optimum level in
all untreatable hypercholesterolemia patients [53].
In 1994, Kroon et al. presented data on a pregnancy in
a 20-year-old woman with homozygous familial hyperchole-
sterolemia and coronary heart disease who was treated with
the Liposorber LA-15 system biweekly [162]. During preg-
nancy and delivery, no signs of maternal coronary insuﬃ-
ciency developed. Serial ultrasonic measurements of fetal
growth indices and the blood ﬂow velocity waveforms of the
urineandumbilicalarteryrevealednosignoffetalgrowthre-
tardation or insuﬃciency of the uteroplacental circulation.
Even in children, the Liposorber system has proved to be safe
and eﬀective. Stefanutti et al. reported in 1997 of a 4.5-year-
old-girl with homozygous familial hypercholesterolemia and
CHD who was treated eﬀectively with LDL apheresis [163].
The decrease of the atherogenic apolipoprotein B-containing
lipoproteins was between 50 and 70 percent. The child tole-
rated the LDL-apheresis without any clinically signiﬁcant
complications. She was submitted to a long-term program of
treatment at biweekly intervals. The experience of these
authors led them to recommend early therapeutic interven-
tion with extracorporeal treatment with LDL-apheresis in
children severely aﬀected by homozygous or double hetero-
zygous familial hypercholesterolemia.
Two clinical reports described excellent long-term fol-
low-up results for patients with coronary artery disease who
had been treated with LDL-apheresis using dextran sulfate
cellulose columns plus adjunctive cholesterol lowering drug
therapy [164]. In addition, there is increasing evidence that
LDL-apheresis is eﬀective for the prevention of extracoro-
naryatheroscleroticdisease,anditisalsoreportedtohavethe
potential to improve microvascular disorders. Since the
mechanisms of clinical improvement caused by LDL aphere-
sisextendsbeyondsimpleanddrasticreductionofLDLchol-
esterol,furtherinvestigationbasedonrecentvascularbiolog-
ical evidence is needed [165]. Intensive cholesterol-loweringThe Scientiﬁc World Journal 11
therapy with LDL-apheresis and lipid-lowering drugs can
achieve a substantial decrease in LDL-cholesterol levels to
induce regression of coronary artery disease [32]. The Lipo-
sorber LA-15 (Kaneka, Japan) system represents a safe and
eﬀective therapy option for patients suﬀering from severe
hypercholesterolemia that could not be adequately controll-
ed by diet and maximum drug therapy.
Complement activation takes place with essentially all
adsorbers; however, activated complement is removed by
bindingtospeciﬁcproteinssuchasC4bindingprotein.Inthe
presence of anticoagulating heparin, bradykinin is formed,
but the production of bradykinin is low and normally not
clinically signiﬁcant [166, 167]. However, drugs that inhibit
angiotensin converting enzyme (ACE inhibitors) can exacer-
bate the clinical eﬀect of this amount of bradykinin to the
point of serious adverse eﬀect including anaphylaxis [168,
169].
Olbricht et al. reported on a anaphylactic reaction in
a patient during ACE inhibition therapy and LDL-apheresis
[169].Heobservedreactionssimilartothosewhichfrequent-
ly occur in ACE inhibition therapy in combination with AN-
G9-high-ﬂux dialysis as well as with reusable polysulphone
membranes in intermittent hemodialysis [170, 171]. The
functioning mechanism of these anaphylactic reactions has
still not been ﬁnally clariﬁed, although they are presumably
induced by the increased release of bradykinin. Bradykinin is
formed through activation of the contact activation system,
which consists of the components: high-molecular-weight
kininogen,prekallikrein,Hagemann’sfactor,andcoagulating
factor XI. When plasma comes into contact with very high-
negatively charged dextran sulfate, the concentration of
bradykinin in the plasma increases considerably [170, 171].
Bradykinin is quickly decomposed through the activity of
kininase IandII;thuspatients undergoinglipid apheresisare
not normally aﬀected.
Kininase II is identical to angiotensin-converting enzyme
and is blocked by the administration of ACE inhibitors. This
results in an increase of bradykinin in the bloodstream and
to an anaphylactic reaction. These anaphylactic reactions are
notspeciﬁctoaparticularmembraneorsurfacetype,butcan
always occur in ACE inhibition when blood or plasma comes
into contact with contact-activating surfaces. The reactions
are independent of the type of ACE inhibitor; the presence
of dialysate is not necessary, for they also develop in cell-free
plasma. The varying degrees of severity are presumably con-
nected to the expression of the ACE-coding gene being sub-
ject to strong individual ﬂuctuations [172]. In the instruc-
tions of the LDL apheresis procedure, there is a contraindi-
cation for ACE inhibitors by LDL-apheresis. ACE inhibitors
must not be administered to patients undergoing LDL-
apheresis [173].
9. Low-DensityLipoproteinHemoperfusion
9.1. DALI System. In 1993, Bosch et al. ﬁrst described low-
density lipoprotein hemoperfusion (direct adsorption of
lipoproteins (DALI), Fresenius, Germany) [174]. The new
adsorber,whichiscompatiblewithhumanwholeblood,uses
a matrix of polyacrylate beads. In the DALI system, blood
is perfused through the adsorber, which contains 480mL of
polyacrylate-coated polyacrylamide, without regeneration.
The column has a capacity of more than 1.5–2.0 blood
volumes for eﬀective adsorption of cholesterol, LDL, Lp(a),
and triglycerides. Regeneration is not necessary because the
column is used for only one treatment [175, 176]. In a very
simple extracorporeal circuit, the blood is pumped through
the LDL adsorber. The elimination of LDL, Lp(a) particles,
and other lipoproteins from whole blood is performed by
adsorption onto polyacrylate-coated polyacrylamide beads
[177]. The small porous beads with a diameter of 150–
200μm are immobilized in the adsorber with the aid of two
sieves. The beads have a porous structure which exploits the
principle of size exclusion chromatography. The sponge-like
structure of the beads oﬀers a very large inner and outer
surface for adsorption (more than 99 percent of the overall
surface of over 1,000m2 is located within the beads).
The adsorption of LDL and Lp(a) and other lipoproteins
occurs by polyacrylate ligands covalently binding to the
polyacrylamide surface. Like the LDL-receptor, polyacrylate,
consists of polyanions, with negatively charged carboxylate
groups [175]. The polyanions interacts selectively with
the cationic groups in the apoprotein B moiety of LDL
and Lp(a). Due to this electrochemical interaction, the
lipoproteins are immobilized on the beads. By ﬂowing, the
whole blood past the beads aﬀects only a minor interaction
between the blood cells and the similarly small outer surface
of the beads [177, 178]. The smaller lipoproteins can easily
penetrate the inner sponge-like structure of the beads via
the pores. HDL can also penetrate the beads, but because
the apo AI-coated HDL is not attracted to the ligand, it
is not aﬀected by the adsorber and cannot be eliminated.
Monitoring of this simple extracorporeal blood circulation
system is carried out by measuring the blood pressure in the
aﬀerent and eﬀerent blood lines and at the adsorber inlet.
Anticoagulation is carried out by ﬁrst applying a heparin
bolus, then by a continuous ACD-A solution infusion into
the blood line as it exits the patient’s vein. In most cases,
an infusion rate of one mL of acid citrate dextrose per 20–
25mL of blood is suﬃcient for adequate anticoagulation of
the extracorporeal circuit. The speed of the ACD-A pump
controls the amount of solution, which is monitored by a
drip counter.
Besides lipoproteins, the DALI system also adsorbs the
positively charged ions calcium and magnesium. Therefore,
the columns have to be prerinsed with 4–6 liters of a prim-
ing solution containing these electrolytes. The adsorber is
thereby saturated with these cations, thus preventing hypo-
calcemia and hypomagnesia during the treatment [178]. The
DALI system can be run at three diﬀerent adsorber sizes
(DALI 500, 750, and 1000mL adsorbers). Special equipment
and tubes are available. After passing the adsorber, the blood
depleted of all apoB-containing lipoproteins is put back into
the patient. The advantages are good selectivity, high eﬀec-
tiveness, and a simple technology. The potential for possible
microparticle release from the columns as with all adsorbers
can be avoided prevented by more and better rinsing of the
columns and a careful handling. A second leucocyte type in12 The Scientiﬁc World Journal
line ﬁlter can be added after column to further reduce the
possibility of microparticle release. Such a ﬁlter is recom-
mended to maximize safety. In a ﬁve-year followup, long-
term therapy with DALI was safe, eﬀective, and selective as
LDL and Lp(a) could be reduced by >60 percent per session
inapproximately100minutestreatmenttime,whiledecrease
and the incidence of side eﬀects were low [179]. The DALI
systemhasproventobesafe,eﬀective,andsimpletoperform.
9.2. Liposorber D. Another whole blood lipoprotein aphere-
sis system (Liposorber D, Kaneka Japan) is commercially
available too. The Liposorber D system is the second whole
blood perfusion type LDL apheresis system developed on
the basis of the technology of the dextran sulfate Liposorber
LA-15 system. Liposorber D adsorbs positively charged LDL,
VLDL, and Lp(a) particles from whole blood using nega-
tively charged polyanions. Liposorber D contains negatively
charged dextran sulfate covalently bound to cellulose [12].
The negatively charged surfaces activate the intrinsic coagu-
lation pathway; prolongation of a PTT and shortening of PT
have been observed in the LDL apheresis with the dextran
sulfate column. Coagulation factors such as factors XI and
XIIwerereducedbydextransulfateadsorption,butthoseco-
agulation factors returned to normal range within one or
two days after the treatment. A Japanese multicenter clinical
trial found a signiﬁcantly reduce in LDL, Lp(a), and tri-
glycerides by using Liposorber D [180]. Adverse events,
which were observed, were hypocalcemia during treatment
caused by ACD-A solutions, the symptoms disappeared by
administration of calcium, and slight hypotension.
From a technical point of view, the Liposorber D whole
blood adsorption column has clear advantages over the usual
LDL-apheresis systems that require plasma separation. The
system is simpler and easier to handle because no plasma se-
paration procedure is necessary. In vitro evaluations have
shown that the adsorbent eﬃciently adsorbs LDL and Lp(a)
withagoodbiocompatibility.Theclinicalresultsofthistech-
nology are very encouraging. The advantages are good selec-
tivity, eﬀectiveness, and a simple technology [12]. Possible
columns conﬁgurations DL 50, DL 75, and DL 100 are avail-
able.
A treatment performed with the Liposorber D and the
new developed machine DX-21 reduces the apoB lipopro-
teins without having great inﬂuence on HDL-C, other im-
portant plasma components or blood cells. Liposorber D
chemically is identical to that for Liposorber LA-15 with a
modiﬁcation of the size of the adsorbent beads suitable for
whole blood processing. The Liposorber D system is com-
parable with the DALI system. The handling with the DX-
21 machine is easy, safe, and the user is guided through all
treatment steps.
In conclusion, the developed whole blood perfusion
LDL-apheresis system Liposorber D is a safe and simple
apheresis system and thus a useful modality to remove LDL-
C and Lp(a) from whole blood in hypercholesterolemic pa-
tients.
(i) LiposorberDisespeciallydesignedtoeliminateLDL-
C and Lp(a) from the whole blood.
(ii) The adsorbent for Liposorber D, dextran sulfate-cell-
ulose, is chemically identical to that for Liposorber
LA-15, with a modiﬁcation of the size of the adsor-
bent beads suitable for the whole blood processing.
(iii) The whole blood processing without plasma separa-
tion provides a simple, easy-handling, and a shorter
operation time.
10. Conclusion of LDL-Apheresis
All of the techniques described above are eﬀective and well
tolerated. With weekly or biweekly treatment, the average
LDL cholesterol concentration can be reduced to approxi-
mately 50–60 percent of the original levels. LDL concentra-
tion increases again after each apheresis session, but does not
return to the original level. After a few sessions, it balances
out.Theincreaseafterapheresiscanbesloweddownbylipid-
lowering drugs. By lowering the cholesterol from 400mg/dL
to 200mg/dL, treatment can almost double a patient’s life
expectancy. In Tables 4–6, results are only given for the pre-
sented observation phase. The LDL-apheresis treatment
must be repeated after the above-mentioned treatment pro-
cedure in homozygous and severe heterozygous FH life-long
or until other better therapy technologies are available.
LDL-apheresis decreases not only LDL mass but also
improves the patient’s life expectancy. LDL-apheresis per-
formed with diﬀerent techniques decreases the susceptibility
o fL D Lt oo x i d a t i o n .T h i sd e c r e a s em a yb er e l a t e dt oat e m -
porary mass imbalance between freshly produced and older
LDL particles. Furthermore, the baseline fatty acid pattern
inﬂuences pretreatment and postreatment susceptibility to
oxidation [25].
Streicher et al. observed that despite drug therapy, LDL-
apheresis signiﬁcantly stimulates the residual LDL-receptor
expression in FH via the reduction of available extracellular
cholesterol resulting in delayed reappearance of hypercholes-
terolemia in between treatments [181]. The acute eﬀect of
lipid apheresis on serum lipidome could be predominantly
attributed to lipoprotein changes, while blood cell damages
during this procedure caused additional, less-pronounced
changes. The importance of speciﬁc changes in particular
lipid species remains to be established [182].
The techniques vary somewhat in selectivity. Cascade
ﬁltrationreducesHDLconcentration,whichprobablyhasan
atherogenous eﬀect in the long term. HELP, cascade ﬁltra-
tion, and dextran sulfate adsorption to a lesser extent, and
whole blood hemoperfusion systems reduce the average
ﬁbrinogen concentration. This reduction can prove advan-
tageous as the viscosity of the blood is reduced and the rheo-
logical characteristics improved. Moreover, ﬁbrinogen is an
independentriskfactorinthedevelopmentofcoronaryheart
disease.
The primary aim in reducing cholesterol concentration
is to prevent the development and progression of atheroscle-
rosis. There are suﬃcient data that this therapeutic aim can
be achieved. There are many reports on decrease and slower
progression of atherosclerotic changes in coronary vessels
and carotids after patients have been treated for one or moreThe Scientiﬁc World Journal 13
Table 7: Guidelines on the use of TA in hyperlipidemia [40, 41].
Apheresis applications committee of ASFA
2007 2010
TA modality Category Category Recommendations
grade
FH, homozygous Selective removal methods TPE I I
II
1A
1C
FH, heterozygous LDL > 300mg/dL Selective removal methods TPE II II 1A
1C
FH heterozygous with CDH Selective removal methods TPE II II —
—
FH during pregnancy Selective removal methods TPE II II —
—
CHD and elevated Lp(a) > 60mg/dL — — — —
Hypertriglyceridemic pancreatitis
(chylomicronemic syndrome) TPE III III 2C
years with lipid apheresis. Selective LDL elimination through
LDL-apheresis represents a decisive breakthrough in the
treatment of high-risk patients with hypercholesterolemia,
whose treatment has, up to now, been inadequate, despite
strict diets and lipid-reducing medication.
The German Federal Committee of Physicians and
Health Insurance Funds criteria for LDL-apheresis are
(1) FH homozygotes,
(2) patients with severe hypercholesterolemia in whom
maximal dietary and drug therapy for >1y e a rh a v e
failed to lower cholesterol suﬃciently [183].
The Apheresis Applications Committee (AAC) of the
ASFA summarized the LDL-apheresis in familial hyperchole-
sterolemia as follows. The goal of LDL-apheresis is to reduce
the time-averaged total cholesterol levels by 45–55 percent,
the LDL levels by 40–60 percent, and the Lp(a) by 40–60 per-
cent [40]. FDA approved indications for patients with FH
unresponsivetopharmacologicanddietarymanagementare
(1) functional homozygotes with a LDL cholesterol
>500mg/dL,
(2) functional heterozygotes with no known cardiovas-
cular disease but a LDL cholesterol >300mg/dL,
(3) functional heterozygotes with known cardiovascular
disease and LDL cholesterol >200mg/dL [40].
Patients without FH but with high LDL or Lp(a) chol-
esterol who cannot tolerate or whose conditions are unre-
sponsive to conventional therapy can also be treated [40].
During pregnancy, LDL cholesterol levels in individuals
aﬀectedbyFHcanrisetoextremelevelsthatcancompromise
uteroplacental perfusion. There are case reports of the use of
LDL-apheresisinthisindicationstoallowforsuccessfulcom-
pletion of pregnancy. TPE can be eﬀective but because of the
availabilityoftheselectiveremovalsystemsandtheirenhanc-
ed eﬃciency of cholesterol removal, the use of TPE to treat
FH is uncommon. It may, however, be the only option in
smallchildren[40].TheguidelinesontheuseofT Ainh yper -
lipidemia are shown in Table 7.
In 2010, the AAC has concerted eﬀort to generate a sys-
tem, which better translates the existing evidence to treat-
ment of the individual patient. The AAC introduced the
grading recommendations 1A, 1B, 1C, 2A, 2B, and 2C
including strong recommendation (1A) to weak recommen-
dation (2C) [41].
A reduction in costs is a valid demand in view of the
scarce resources available in the healthcare system. Commis-
sions,consistingofphysicians,administrationspecialistsand
representatives of the health insurance funds and others,
nowadays decide at a “round table” who will be granted
medical facilities and who will not, this is a clinical routine
adopted only in Germany. Physicians are committed to
helping all the patients entrusted to them to the best of their
knowledge, and this means that medical treatment—and
particularly the apheresis processes—must become aﬀord-
able. This demand represents a great challenge to physicians,
politicians, health organisations, and, above all, to the man-
ufacturers. Industry constantly justiﬁes the high costs with
the extensive research and development required. All those
involved in the healthcare system must intensify their co-
operation in this respect.
Nevertheless, medical progress is advancing and will not
be stopped. Since the introduction of hollow ﬁber mem-
branes, exceptional eﬀorts in research and development have
been undertaken in the apheresis sector alone, enabling, for
example, the introduction of selective separation techniques
into everyday clinical practice—techniques which were
unthought of—at the beginning of the eighties. This is re-
ﬂected in the numerous national and international specialist
congresses, which take place each year.
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